Hardman Johnston Global Advisors LLC lowered its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 18.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 482,657 shares of the company's stock after selling 109,661 shares during the quarter. Hardman Johnston Global Advisors LLC owned approximately 0.07% of Genmab A/S worth $15,368,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in Genmab A/S by 42.7% during the 1st quarter. JPMorgan Chase & Co. now owns 135,116 shares of the company's stock valued at $4,889,000 after acquiring an additional 40,444 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Genmab A/S by 4.2% during the 1st quarter. Bank of New York Mellon Corp now owns 116,847 shares of the company's stock valued at $4,227,000 after acquiring an additional 4,665 shares in the last quarter. Private Advisor Group LLC grew its stake in Genmab A/S by 24.0% during the 1st quarter. Private Advisor Group LLC now owns 20,119 shares of the company's stock valued at $728,000 after acquiring an additional 3,891 shares in the last quarter. BlackRock Inc. grew its stake in Genmab A/S by 1.6% during the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company's stock valued at $198,799,000 after acquiring an additional 86,571 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Genmab A/S by 18.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,243 shares of the company's stock valued at $660,000 after acquiring an additional 2,792 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.
Genmab A/S Price Performance
GMAB traded down $0.48 on Friday, hitting $29.26. The company had a trading volume of 413,219 shares, compared to its average volume of 606,834. The company's fifty day moving average price is $29.27 and its 200 day moving average price is $30.52. Genmab A/S has a 1-year low of $26.32 and a 1-year high of $42.99. The stock has a market cap of $19.33 billion, a price-to-earnings ratio of 30.48, a price-to-earnings-growth ratio of 2.15 and a beta of 0.99.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The firm had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. On average, sell-side analysts forecast that Genmab A/S will post 1.06 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms have weighed in on GMAB. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, April 4th. Morgan Stanley reissued an "underweight" rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Citigroup cut Genmab A/S from a "neutral" rating to a "sell" rating in a research note on Monday, January 22nd. Truist Financial reissued a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. Finally, BMO Capital Markets raised Genmab A/S from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Genmab A/S currently has an average rating of "Hold" and a consensus target price of $48.50.
View Our Latest Report on Genmab A/S
Genmab A/S Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
